Close

Galapagos NV (GLPG) Doses First Patient in DIVERSITY Phase 3 Crohn's Disease Study; Earns $50M Milestone from Gilead (GILD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. IBM
4. HCP
5. PI
6. BSX
7. LRCX
8. BA
9. BIIB
10. F


Go back to Galapagos NV (GLPG) Doses First Patient in DIVERSITY Phase 3 Crohn's Disease Study; Earns $50M Milestone from Gilead (GILD)

Phase 3 study with filgotinib initiated in Crohn's disease

November 22, 2016 4:04 PM EST

MECHELEN, Belgium, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reports the first dosing of a patient in the DIVERSITY Phase 3 study with filgotinib in Crohn's disease (CD). The start of the DIVERSITY study triggers a $50 million milestone payment from Gilead.

The worldwide DIVERSITY Phase 3 study will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo in 1,320 patients with moderately to severely active Crohn's disease, including those with prior biological therapy failure.

"With the FITZROY Phase 2 study,... More